How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,047 results for

Procainamide

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery

antibody therapies Pregnant or breastfeeding Evidence of corrected QT (QTc) prolongation on pretreatment electrocardiography (ECG) (greater than 440 ms in males or greater than 460 ms in females) Lab values that in the opinion of the primary surgeon would prevent surgical resection Patients receiving class IA (quinidine, procainamide) or class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents Contacts and Locations Go to Information from the National Library of Medicine To learn more about

2017 Clinical Trials

162. Buprenorphine Transdermal Patches in Arthroscopic Rotator Cuff Repair

and Scopolamine, Antiarrhythmics, Amiodarone, Disopyramide, Dofetilide, Procainamide, Quinidine and Sotalol. Anticonvulsants; Carbamazepine, Phenobarbital, Phenytoin and Rifampin) History of previous surgeries in shoulder treated with RAMR Previous neuromuscular deficit Febrile Syndrome Autoimmune or Rheumatologic Disease History of intestinal transit disorders (paralytic ileus) History of alcohol or drug abuse Patients in psychological or psychiatric treatment for anxiety disorders, personality disorders

2017 Clinical Trials

163. Mirabegron in Achalasia: A Clinical and Manometric Proof of Concept Pilot Study

, procainamide, disopyramide, propafenone, azole antifungals, fluoroquinolones, macrolide antibiotics, HIV antiretrovirals, chemotherapy, beta-2 agonists, tricyclic antidepressants, selective serotonin reuptake inhibitors Prior surgeries for achalasia < 2 months since last endoscopic botulinum toxin injection into LES or endoscopic dilation Stage 4 Chronic kidney disease (severe renal impairment with GFR 15-29 ml/min), Stage 5 Chronic Kidney disease (GFR < 15 ml/min or on dialysis) Childs Pugh B (moderate

2017 Clinical Trials

164. Genomics and Epigenomics for New Insights in fEmale OAB (GENIE) Study

that influence DNA methylation: hydralazine, procainamide, methotrexate, valproic acid, tamoxifen, raloxifene, letrozole, anastrozole (Arimidex), or exemestane (Aromasin) Any history of urinary tract malignancy (bladder, urethra, ureter, kidney) Intradetrusor Botox injection within the prior 12 months Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided

2017 Clinical Trials

165. Effects of Anamorelin on Cancer-Related-Fatigue in Patients With Advanced Cancer

with strong CYP 3A4 inhibitors within the previous two weeks (ketoconazole, clarithromycin, itraconazole, nefazodone, telithromycin) Patients on drugs that may prolong the PR or QRS interval durations, such as any of the Class I/Sodium (Na+) Channel blocking antiarrhythmic medications should be avoided (e.g. Flecainide, Procainamide, Propafenone, Quinidine). Patients with untreated clinically relevant hypothyroidism Patients currently on investigational therapies will be evaluated by the PI on a case

2017 Clinical Trials

166. The Role of Electrophysiology Testing in Survivors of Unexplained Cardiac Arrest

for eligibility information Ages Eligible for Study: Child, Adult, Older Adult Sexes Eligible for Study: All Accepts Healthy Volunteers: No Sampling Method: Non-Probability Sample Study Population Survivors of unexplained sudden cardiac death for whom an underlying etiology remains unclear following a standard diagnostic workup, including 12-lead surface ECG, coronary artery assessment, echocardiography, cardiac MRI with late gadolinium enhancement, procainamide challenge, and exercise treadmill testing

2017 Clinical Trials

167. A Study to Assess the Safety and Tolerability Profile of TR399 in Healthy Volunteers and Erectile Dysfunction Patients

disorder that is not suitable for sexual activities. Use of antiarrhythmic agents class IA (such as quinidine, or procainamide) and class III (such as amiodarone or sotalol) within 2 weeks prior to the screening visit With priapism, such as sickle cell anemia, multiple myeloma or leukemia Phase IIa Known or suspected allergy, hypersensitivity, or intolerance to any ingredients of study product Participated in another clinical trial and received any investigational drug within four weeks prior (...) cardiovascular disorder that is not suitable for sexual activities. Use of antiarrhythmic agents class IA (such as quinidine, or procainamide) and class III (such as amiodarone or sotalol), within 2 weeks prior to the screening visit With priapism, such as sickle cell anemia, multiple myeloma or leukemia Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided

2017 Clinical Trials

168. Image Guided Surgery for Margin Assessment of Head and Neck Cancer Using Cetuximab-IRDye800CW cONjugate

IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents. Magnesium, potassium and calcium lower than the lower limit of normal range. Life expectancy < 12 weeks Karnofsky performance status < 70% Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its

2017 Clinical Trials

169. Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer

screening visit; > class 2 New York Heart Association heart failure; or > class 2 angina pectoris; or receiving quinidine, procainamide, disopyramide, amiodarone, dronedarone, arsenic, dofetilide, sotalol, or methadone. Please also see prohibited medication/therapy (Section 5.4.10.1) Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor

2017 Clinical Trials

170. Study of Varlitinib Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer

jeopardize the safety of the patient or the validity of the study results. Have a baseline corrected QT interval > 450 ms or patients with known long QT syndrome, torsade de pointes, symptomatic ventricular tachycardia, unstable cardiac syndrome in the past 3 months before screening visit, > class 2 NYHA (The New York Heart Association Functional Classification heart failure), > grade 2 CCS (the Canadian Cardiovascular Society Guidelines) angina pectoris, or receiving quinidine, procainamide

2017 Clinical Trials

171. Safety and Efficacy of Various Doses and Treatment Durations of Linezolid Plus Bedaquiline and Pretomanid in Participants With Pulmonary TB, XDR-TB, Pre- XDR-TB or Non-responsive/Intolerant MDR-TB (ZeNix)

foresees potential risks for serotonin syndrome when combined with linezolid. Concomitant use of any drug known to prolong QTc interval (including, but not limited to, amiodarone, bepridil, chloroquine, chlorpromazine, cisapride, cyclobenzaprine, clarithromycin, disopyramide, dofetilide, domperidone, droperidol, erythromycin, fluoroquinolones, halofantrine, haloperidol, ibutilide, levomethadyl, mesoridazine, methadone, pentamidine, pimozide, procainamide, quinidine, sotalol, sparfloxacin, thioridazine

2017 Clinical Trials

172. Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid

to prolong the QTc interval (erythromycin, clarithromycin, astemizole, type Ia [quinidine, procainamide, disopyramide] and III [amiodarone, sotalol] anti-arrhythmics, carbamazepine, sulfonylureas, and meperidine), within 30 days before the first dose of study drug or during the study drug treatment period. Use of any adrenergic/serotonergic agonists, such as pseudoephedrine and phenylpropanolamine (frequently found in cold and cough remedies), within 7 days before the first dose of study drug or during

2017 Clinical Trials

173. Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer

3 months before screening visit, > class 2 New York Heart Association heart failure, > grade 2 Canadian cardiovascular society angina pectoris, or receiving quinidine, procainamide, disopyramide, amiodarone, dronedarone, arsenic, dofetilide, or sotalol methadone. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer

2017 Clinical Trials

174. Study to Evaluate Effects of Vorinostat and HXTC on Persistent HIV-1 Infection in HIV-Infected Subjects Started on ART

a fully active alternative cART regimen based on previous resistance testing and/or treatment history. Use of the following medications that carry risk of torsade des pointes: amiodarone, arsenic trioxide, astemizole, bepridil, chloroquine, chlorpromazine, cisapride, clarithromycin, disopyramide, dofetilide, domperidone, droperidol, erythromycin, halofantrine, haloperidol, ibutilide, levomethadyl, mesoridazine, methadone, pentamidine, pimozide, probucol, procainamide, quinidine, sotalol, sparfloxacin

2017 Clinical Trials

175. Phase IV Study to Evaluate Bone Mineral Density in No-bone Metastatic Prostate Cancer Treated With Degarelix

of Firmagon® patients who receive concomitant medications that might prolong the QT interval, in particular class I A (such as quinidine, procainamide, disopyramide,) or class III antiarrhythmics (such as amiodarone, sotalol, dofetilide, ibutilide) patients with history of or risk factors for Torsades de Pointes patients who take either methadone or moxifloxacin or antipsychotic patients with alteration in electrolyte blood levels (such as sodium, potassium, calcium and magnesium) patients with severe

2017 Clinical Trials

176. Management of Electrical Storm

) Start an antiarrhythmic. My preference is procainamide, based on the . (Ortiz 2017) Procainamide 10 mg/kg over 20 minutes I think the benefit of amiodarone has been oversold for most conditions, but it is a reasonable second line option here. (Many authors list it as their first option, but with limited evidence). Chronic use of amiodarone has been shown to decrease the incidence of frequent ventricular dysrhythmias in these patients. (Connolly 2006) Boluses of 150mg, followed by an infusion of 1 mg (...) journal : official journal of the Japanese Circulation Society. 2010; 74(5):856-63. [ ] Nademanee K, Taylor R, Bailey WE, Rieders DE, Kosar EM. Treating electrical storm : sympathetic blockade versus advanced cardiac life support-guided therapy. Circulation. 2000; 102(7):742-7. [ ] Ortiz M, Martin A, et al. Randomized comparison of intravenous procainamide versus intravenous amiodarone for the acute treatment of tolerated wide QRS tachycardia: the PROCAMIO study. Eur Heart J. 2017 38;1329-1335. Patel

2019 First10EM

177. Ottawa Aggressive Atrial Fibrillation Protocol

Administration 4 Ottawa Aggressive Atrial Fibrillation Protocol Ottawa Aggressive Atrial Fibrillation Protocol Aka: Ottawa Aggressive Atrial Fibrillation Protocol , Chemical Cardioversion of Acute Atrial Fibrillation With Procainamide From Related Chapters II. Indications: Cardioversion Acute onset of within prior 48 hours III. Contraindications: Cardioversion Hemodynamically unstable (immediate cardioversion indication) Acute Unclear onset (anticoagulate, no cardioversion and follow-up as below) Cannot (...) confirm onset <48 hours IV. Protocol: Step 1 - Rate Control (optional) Indications Symptomatic or Not planning cardioversion and >110 Medications 0.25 mg/kg over 10 min (may repeat at 0.35 mg/kg) 5 mg IV every 15 min as needed (typically up to 3 doses) V. Protocol: Step 2 - Chemical Cardioversion with Procainamide Indications Hemodynamically stable with systolic >100 mmHg No contraindications (see above) Normal and Method 1 g IV over 60 minutes Monitor with frequent s, and hold if systolic <100 mmHg

2018 FP Notebook

178. Ottawa Aggressive Atrial Fibrillation Protocol

Administration 4 Ottawa Aggressive Atrial Fibrillation Protocol Ottawa Aggressive Atrial Fibrillation Protocol Aka: Ottawa Aggressive Atrial Fibrillation Protocol , Chemical Cardioversion of Acute Atrial Fibrillation With Procainamide From Related Chapters II. Indications: Cardioversion Acute onset of within prior 48 hours III. Contraindications: Cardioversion Hemodynamically unstable (immediate cardioversion indication) Acute Unclear onset (anticoagulate, no cardioversion and follow-up as below) Cannot (...) confirm onset <48 hours IV. Protocol: Step 1 - Rate Control (optional) Indications Symptomatic or Not planning cardioversion and >110 Medications 0.25 mg/kg over 10 min (may repeat at 0.35 mg/kg) 5 mg IV every 15 min as needed (typically up to 3 doses) V. Protocol: Step 2 - Chemical Cardioversion with Procainamide Indications Hemodynamically stable with systolic >100 mmHg No contraindications (see above) Normal and Method 1 g IV over 60 minutes Monitor with frequent s, and hold if systolic <100 mmHg

2018 FP Notebook

179. Administration of medicinal products by non - medical personnel as part of Clinical Nuclear Medicine Procedures

syndrome) may reduce the excretion of procainamide and N- acetylprocainamide resulting in increased plasma level of these drugs. 3) Alteration of gastric pH: The bioavailability of certain drugs may be affected. This can result in either an increase in absorption (e.g. triazolam, midazolam, glipizide) or a decrease in absorption (e.g. ketoconazole, atazanavir, delaviridine, gefitnib).. Contraindications Ranitidine is contraindicated for patients known to have hypersensitivity to any component

2013 British Nuclear Medicine Society

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>